Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The update appears to show only minor layout adjustments with no changes to the core study content, such as design, endpoints, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T13:44:06.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    30 days ago
    Change Detected
    Summary
    Core content updated with new government-status notice and version 3.2.0; a specific resource entry (Small cell lung carcinoma) was deleted (v3.1.0).
    Difference
    4%
    Check dated 2025-10-06T04:13:58.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    - Updated the page version from v3.0.2 to v3.1.0. Minor overall impact, mainly reflects a version increment.
    Difference
    0.1%
    Check dated 2025-09-28T23:35:17.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Updated the page from v3.0.1 to v3.0.2; removed the Back to Top link as a minor UI cleanup. No changes to pricing, stock availability, or time slots.
    Difference
    0.2%
    Check dated 2025-09-14T09:49:42.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-07T07:45:36.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of specific facility names and locations in Italy, as well as new drug names related to cancer treatment. Notably, previous entries related to lung cancer and various antineoplastic agents have been removed.
    Difference
    5%
    Check dated 2025-08-31T01:00:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.